Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery

Clinical Immunology

Volumn 124, Issue 2, 2007, Pages 200-206

  Singh, K P ^a   Howard, J L ^b   Wild, S P ^b   Jones, S L ^b   Hoy, J ^a,c   Lewin, S R ^a,c  

^a ALFRED HOSPITAL   (Australia)

^b Cellestis Limited   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

CD8+ T cell immune response; Cytomegalovirus; HIV; Interferon gamma

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; PRIORITY JOURNAL; RISK FACTOR; VIRUS LOAD;

ADULT; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HIV; HIV INFECTIONS; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED;

EID: 34447296435     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.04.018     Document Type: Article

References (29)

1. Mocarski E.S., and Courcelle C.T. Cytomegalovirus and their replication. In: Fields B., Knipe D.M., and Howley P. (Eds). Virology. 4th ed. (2001), Raven Press, New York 2626
2. Hoover D.R., Saah A.J., Bacellar H., Phair J., Detels R., Anderson R., and Kaslow R.A. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N. Engl. J. Med. 329 26 (1993) 1922-1926
3. Steininger C., Puchhammer-Stockl E., and Popow-Kraupp T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J. Clin. Virol. 37 1 (2006) 1-9
4. Pertel P., Hirschtick R., Phair J., Chmiel J., Poggensee L., and Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 5 11 (1992) 1069-1074
5. Deayton J.R., Mocroft A., Wilson P., Emery V.C., Johnson M.A., and Griffiths P.D. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 13 (1999) 1203
6. O'Sullivan C.E., Drew W.L., McMullen D.J., Miner R., Lee J.Y., Kaslow R.A., Lazar J.G., and Saag M.S. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. J. Infect Dis. 180 3 (1999) 847-849
7. Crum N., and Blade K.A. Cytomegalovirus retinitis after immune reconstitution. AIDS Read. 15 4 (2005) 186-188
8. Johnson S.C., Benson C.A., Johnson D.W., and Weinberg A. Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clin. Infect. Dis. 32 5 (2001) 815-819
9. + T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy. J. Infect. Dis. 183 9 (2001) 1399-1404
10. Weinberg A., Wohl D.A., Barrett R.J., and van der Horst C. Inconsistent reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J. Infect. Dis. 184 6 (2001) 707-712
11. Gandhi M.K., and Khanna R. Human cytomegalovirus: clinical aspects, immune regulation and emerging treatments. Lancet, Infect. Dis. 12 (2004) 725-738
12. +-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J. Virol. 77 9 (2003) 5226-5240
13. Sacre K., Carcelain G., Cassoux N., Fillet A.M., Costagliola D., Vittecoq D., Salmon D., Amoura Z., Katlama C., and Autran B. Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J. Exp. Med. 201 12 (2005) 1999-2010
14. + cell early maturational phenotype. J. Infect. Dis. 194 11 (2006) 1537-1546
15. Ghanekar S.A., Nomura L.E., Suni M.A., Picker L.J., Maecker H.T., and Maino V.C. Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin. Diagn. Lab. Immunol. 8 3 (2001) 628-631
16. Weinberg A., Wohl D.A., MaWhinney S., Barrett R.J., Brown D.G., Glomb N., and van der Horst C. Cytomegalovirus-specific IFN-gamma production is associated with protection against cytomegalovirus reactivation in HIV-infected patients on highly active antiretroviral therapy. AIDS 17 17 (2003) 2445-2450
17. +/interferon-gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. J. Infect. Dis. 189 8 (2004) 1362-1373
18. Weinberg A., Tierney C., Kendall M.A., Bosch R.J., Patterson-Bartlett J., Erice A., Hirsch M.S., Polsky B., and AIDS Clinical Trials Group 360 Team. Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy. J. Infect. Dis. 193 4 (2006) 488-493
19. ®-HCMV. Transplant Infect. Dis. (2007) 10.1111/j.1399-3062.2006.00199.x
20. Mori T., Sakatani M., Yamagishi F., Takashima T., Kawabe Y., Nagao K., Shigeto E., Harada N., Mitarai S., Okada M., Suzuki K., Inoue Y., Tsuyuguchi K., Sasaki Y., and Mazurek G.H. Tsuyuguchi I specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am. J. Respir. Crit. Care Med. 170 (2004) 59-64
21. + T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J. Virol. 79 5 (2005) 3038-3051
22. Howden B.P., Michaelides A., Spelman D.W., Spencer A., Schwarer A.P., Wesselingh S., and Kotsimbos T.C. Cytomegalovirus viral load monitoring after allogeneic bone marrow transplantation in patients receiving antiviral prophylaxis. Bone Marrow Transplant. 32 8 (2003) 795-800
23. Metz C.E. Basic principles of ROC analysis. Semin. Nucl. Med. 8 4 (1978) 283-298
24. Maecker H.T., Dunn H.S., Suni M.A., Khatamzas E., Pitcher C.J., Bunde T., Persaud N., Trigona W., Fu T.M., Sinclair E., Bredt B.M., McCune J.M., Maino V.C., Kern F., and Picker L.J. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 255 1-2 (2001) 27-40
25. + T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J. Clin. Invest. 99 7 (1997) 1739-1750
26. Lewin S.R., Ribeiro R.M., Kaufmann G.R., Smith D., Zaunders J., Law M., Solomon A., Cameron P.U., Cooper D., and Perelson A.S. Dynamics of T cells and TCR excision circles differ after treatment of acute and chronic HIV infection. J. Immunol. 169 8 (2002) 4657-4666
27. Brenchley J.M., Price D.A., Schacker T.W., Asher T.E., Silvestri G., Rao S., Kazzaz Z., Bornstein E., Lambotte O., Altmann D., Blazar B.R., Rodriguez B., Teixeira-Johnson L., Landay A., Martin J.N., Hecht F.M., Picker L.J., Lederman M.M., Deeks S.G., and Douek D.C. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12 12 (2006) 1365-1371
28. + T lymphocyte reactivity and protective immunity against acquired immunodeficiency syndrome-related CMV retinitis. J. Infect. Dis. 186 11 (2002) 1701-1702
29. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat. Med. 4 8 (1998) 953-956